Kala Pharmaceuticals Stock Price

0.15 (2.0%)
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Kala Pharmaceuticals Inc KALA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.15 2.0% 7.64 05:17:52
Open Price Low Price High Price Close Price Prev Close
Bid Price Ask Price Spread News
7.50 7.60 0.10 - -
Trades Volume Avg Volume 52 Week Range
6 599 2,051,359 5.04 - 14.68
Last Trade Time Type Quantity Stock Price Currency
05:52:58 99 $ 7.59 USD

Kala Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 428.30M 56.06M 21.65M $ - $ - -2.76 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 2.00 1.40%

more financials information »

Kala Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical KALA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week7.597.737.417.551,442,1910.050.66%
1 Month7.568.146.617.292,265,7930.081.06%
3 Months7.658.146.077.211,877,753-0.01-0.13%
6 Months11.1011.416.077.771,407,466-3.46-31.17%
1 Year6.3114.685.048.451,295,0231.3321.08%
3 Years15.4718.303.248.30617,708-7.83-50.61%
5 Years16.7026.753.249.00569,304-9.06-54.25%

Kala Pharmaceuticals Description

Kala Pharmaceuticals Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY Mucus Penetrating Particles, technology, with an initial focus on the treatment of eye diseases. AMPPLIFY particles are selectively-sized nanoparticles and have proprietary coatings. It has applied the AMPPLIFY technology to create nanosuspensions of loteprednol etabonate, or LE, acorticosteroid designed for ocular applications, resulting in two product candidates. INVELTYS was approved in August 2018 for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25 per cent is in Phase 3 development for the temporary relief of the signs and symptoms of dry eye disease.

Your Recent History
Kala Pharm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.